S

hares of Biogen (BIIB) dropped more than 3 percent Thursday after the Cambridge, Mass., biotech reported that an experimental Alzheimer’s drug it’s co-developing with a Japanese company showed disappointing results in a mid-stage clinical trial.

But the setback affects only one of a half-dozen compounds Biogen is developing to target Alzheimer’s disease, the memory-ravaging neurodegenerative disorder that is expected to affect about one in nine baby boomers and cost the nation $1 trillion by 2050.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy